Chinese drug loberamisal extends stroke treatment window to 2 days

A large-scale clinical trial involving nearly 1,000 patients across 32 hospitals found that the Chinese drug loberamisal extends the stroke treatment window from 6 hours to 2 days. The trial demonstrated a 13 percent improvement in recovery compared to standard care alone. This finding could significantly impact stroke treatment protocols and patient outcomes.

Originally published by gnews